Free Trial

Femasys (FEMY) Competitors

$1.18
0.00 (0.00%)
(As of 05/31/2024 ET)

FEMY vs. POCI, BLUA, KRMD, SRTS, HSAQ, ALUR, PDEX, NVNO, NSPR, and MGRM

Should you be buying Femasys stock or one of its competitors? The main competitors of Femasys include Precision Optics (POCI), BlueRiver Acquisition (BLUA), KORU Medical Systems (KRMD), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), enVVeno Medical (NVNO), InspireMD (NSPR), and Monogram Orthopaedics (MGRM). These companies are all part of the "medical" sector.

Femasys vs.

Precision Optics (NASDAQ:POCI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, community ranking, analyst recommendations and institutional ownership.

Precision Optics has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.76, suggesting that its stock price is 376% less volatile than the S&P 500.

Femasys has a consensus target price of $11.67, indicating a potential upside of 888.70%. Given Precision Optics' higher possible upside, analysts clearly believe Femasys is more favorable than Precision Optics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision Optics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Femasys
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Precision Optics has a net margin of -8.43% compared to Precision Optics' net margin of -1,420.59%. Femasys' return on equity of -19.07% beat Precision Optics' return on equity.

Company Net Margins Return on Equity Return on Assets
Precision Optics-8.43% -19.07% -11.81%
Femasys -1,420.59%-104.06%-73.32%

Femasys received 22 more outperform votes than Precision Optics when rated by MarketBeat users. Likewise, 64.71% of users gave Femasys an outperform vote while only 0.00% of users gave Precision Optics an outperform vote.

CompanyUnderperformOutperform
Precision OpticsOutperform Votes
No Votes
Underperform Votes
2
100.00%
FemasysOutperform Votes
22
64.71%
Underperform Votes
12
35.29%

13.7% of Precision Optics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 16.3% of Precision Optics shares are owned by company insiders. Comparatively, 16.4% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Femasys had 1 more articles in the media than Precision Optics. MarketBeat recorded 3 mentions for Femasys and 2 mentions for Precision Optics. Femasys' average media sentiment score of 1.43 beat Precision Optics' score of 0.96 indicating that Precision Optics is being referred to more favorably in the media.

Company Overall Sentiment
Precision Optics Positive
Femasys Positive

Precision Optics has higher revenue and earnings than Femasys. Precision Optics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision Optics$21.05M1.85-$140K-$0.28-22.96
Femasys$1.07M24.50-$14.25M-$0.84-1.40

Summary

Femasys beats Precision Optics on 9 of the 17 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Sign up to receive the latest news and ratings for FEMY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FEMY vs. The Competition

MetricFemasysSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$26.22M$3.89B$5.17B$7.99B
Dividend YieldN/A1.80%2.76%4.00%
P/E Ratio-1.409.55110.1214.93
Price / Sales24.5070.772,386.0773.53
Price / CashN/A48.0435.4131.55
Price / Book1.695.075.544.59
Net Income-$14.25M$4.50M$106.07M$213.90M
7 Day Performance-7.81%1.27%1.14%0.87%
1 Month Performance-4.45%-1.49%0.65%1.82%
1 Year Performance61.64%-17.83%2.69%5.90%

Femasys Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
POCI
Precision Optics
0 of 5 stars
$6.43
-1.7%
N/A-6.8%$39.69M$21.05M-22.9684Short Interest ↓
Positive News
BLUA
BlueRiver Acquisition
0 of 5 stars
$11.04
-0.5%
N/AN/A$96.92MN/A0.003
KRMD
KORU Medical Systems
3.0845 of 5 stars
$2.13
+0.9%
$3.50
+64.3%
-42.0%$96.56M$28.52M-7.6182Positive News
SRTS
Sensus Healthcare
3.8326 of 5 stars
$5.42
-4.2%
$10.00
+84.5%
+99.3%$92.78M$24.41M18.6935Short Interest ↑
HSAQ
Health Sciences Acquisitions Co. 2
0 of 5 stars
$6.67
-4.7%
N/A-57.6%$74.78MN/A0.004Gap Down
ALUR
Allurion Technologies
2.4485 of 5 stars
$1.51
flat
$5.00
+231.1%
N/A$72.40M$53.47M-0.40501Short Interest ↓
PDEX
Pro-Dex
0 of 5 stars
$19.71
+0.6%
N/A+3.8%$67.01M$46.09M33.98145Short Interest ↓
NVNO
enVVeno Medical
0.4267 of 5 stars
$4.77
-1.0%
N/A+60.6%$64.25MN/A-2.8719Positive News
NSPR
InspireMD
1.6277 of 5 stars
$2.64
+3.1%
$4.85
+83.7%
+48.6%$63.82M$6.20M-3.4765
MGRM
Monogram Orthopaedics
0.251 of 5 stars
$1.99
-0.5%
N/A-58.3%$63.34M$370,000.00-3.9828Short Interest ↑
Gap Up

Related Companies and Tools

This page (NASDAQ:FEMY) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners